JAGX Reviews Strategic Alternatives
Jaguar Health's board initiates review of strategic alternatives to maximize shareholder value ahead of NDA filing for Crofelemer candidate.
Jaguar Health Board Initiates Review Of Strategic Alternatives To Maximize Shareholder Value, Aligned With Anticipated NDA Filing For Crofelemer Candidate In Rare Intestinal Failure Diseases